AnorMED completes public offering of US$100 million

Represented AnorMED Inc., a local biotechnology company, in connection with three bought deal short form prospectus offerings and a special warrant prospectus offering, and in connection with its initial public offering and listing of its Common Shares on the Toronto Stock Exchange totaling more than $100 million.